All News

Michael Crotty, MD, an expert in obesity medicine, discusses GLP-1RAs in the context of weight loss, including the novel dual agonist survodutide.

EADV 2025: Guttman-Yassky has great confidence in the future of agents that block the OX40 pathway, suggesting that they have the potential for disease modification.

Seniors remain protected along with any adult or child with underlying risk factors for severe disease, but the healthy US population is left with a choice, so far.

Corticosteroids following resolution of anaphylaxis should be chosen with clear, clinical rationale and reserved for select children, study authors concluded.

The new study, based in China, will validate urine-based genetic methylation testing which concentrates trace amounts of HPV DNA by more than 10,000 times.

FDA approves guselkumab as the first fully subcutaneous IL-23 inhibitor for ulcerative colitis, showing significant clinical benefits in trials.

The ACIP on September 19 narrowly voted against requiring a prescription to get the shot but urged more detailed discussion of vaccine risks during shared decision making conversations.

Your daily dose of the clinical news you may have missed.

Explore essential insights on cervical cancer screening, patient engagement, and innovative self-collection methods this Gynecologic Cancer Awareness Month.

If approved, the nonhormonal drug could offer an important new option for postmenopausal women seeking alternatives to hormone therapy.